Sep 25 CLEANSLATE STATEMENT ON FDA’s BENZODIAZEPINES NOT CAUSE TO DENY METHADONE OR BUPE
CleanSlate welcomes this clinical guidance from the FDA which reinforces the importance of ongoing maintenance medication to treat opioid addiction. We recognize the increased risk to patients on buprenorphine if they use benzodiazepines like Klonopin or Xanax or Valium.
We will continue to see these patients more often and provide additional structure, strongly encouraging our patients to work with CleanSlate and their other providers to gain the skills and supports necessary to abstain from the abuse of all drugs. However, we applaud the FDA for giving this clinical clarification – it is simply more dangerous for a person with opioid addiction to stop their maintenance buprenorphine than to use or abuse other substances while on maintenance medication. We hope that state regulators and insurance companies will embrace this clinical guidance as well.